Collegium Pharmaceutical (NASDAQ:COLL) Cut to “Buy” at Wall Street Zen

Wall Street Zen lowered shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research note released on Saturday morning.

Other research analysts also recently issued research reports about the stock. Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 24th. HC Wainwright upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 target price on the stock in a research report on Monday, August 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $42.33.

Collegium Pharmaceutical Stock Up 2.7%

Shares of NASDAQ COLL opened at $34.85 on Friday. The company has a market capitalization of $1.10 billion, a P/E ratio of 33.51 and a beta of 0.65. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $39.95. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.10 and a current ratio of 1.18. The company’s 50 day moving average price is $36.25 and its 200-day moving average price is $31.83.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. The firm had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a net margin of 5.13% and a return on equity of 97.28%. Equities analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical declared that its board has authorized a stock buyback program on Monday, July 7th that allows the company to buyback $150.00 million in outstanding shares. This buyback authorization allows the specialty pharmaceutical company to reacquire up to 15.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 17,478 shares of the business’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $38.42, for a total transaction of $671,504.76. Following the completion of the sale, the executive vice president directly owned 70,264 shares of the company’s stock, valued at $2,699,542.88. The trade was a 19.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Gordon Freund sold 11,659 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $34.36, for a total transaction of $400,603.24. Following the completion of the sale, the director owned 23,129 shares in the company, valued at $794,712.44. This represents a 33.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,792 shares of company stock valued at $2,084,207 over the last ninety days. 2.51% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. CWM LLC raised its position in Collegium Pharmaceutical by 453.9% in the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,153 shares during the last quarter. Wealthquest Corp bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $62,000. EverSource Wealth Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Collegium Pharmaceutical by 368.9% in the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,169 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 304.6% in the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 2,294 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.